Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 15/20 | 0.69 |
| ▸ | GLRB | P48167 | 15/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 0.69 |
| ▸ | SCN1A | P35498 | 1/20 | 0.69 |
| ▸ | TAS2R46 | P59540 | 1/20 | 0.69 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.69 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Strychnine SCHEMBL21985190 | 0.82 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL14117483 | 0.82 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL14029424 | 0.82 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL14047653 | 0.82 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL12549549 | 0.82 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| SCHEMBL24177883 | 0.81 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL15475787 | 0.81 | GLRA1 (0.95) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| SCHEMBL4654859 | 0.81 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL184168 | 0.81 | GLRA1 (0.98) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL25300604 | 0.81 | GLRA1 (0.98) | GLRA1GLRBCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452464-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2019-03-13 | — | — | EP | disclosed |
| EP-3380474-A1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-10-03 | — | — | EP | disclosed |
| EP-3262035-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2018-01-03 | — | — | EP | disclosed |
| WO-2017191098-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017089390-A1 | JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-01 | — | — | WO | disclosed |
| EP-3145929-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| EP-3077384-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | F. Hoffmann-La Roche AG (CH) | 2016-10-12 | — | — | EP | disclosed |
| WO-2016135163-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-01 | — | — | WO | disclosed |
| EP-3036230-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| EP-3036229-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| WO-2016001341-A1 | SULFONYLAMINOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-07 | — | — | WO | disclosed |
| WO-2015177326-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-26 | — | — | WO | disclosed |
| EP-2900657-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
| WO-2015082583-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015025026-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015025025-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |